GAD2 and type 1 diabetes mellitus: Notwithstanding the above, a high safety profile of GAD65 Alum, T-cell phenotype alteration, and its promising effect in stage 1 T1D patients can yet make it an effective agent for preventative and combinatory treatments in prediagnosed antibody-positive high-risk groups.